Gilead Sciences (NQ:GILD)

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles ↗

September 23, 2024

Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining...

Via Benzinga

Topics Product Recall

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

September 23, 2024

The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital.

Via MarketBeat

Topics ETFs Economy

AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug ↗

September 23, 2024

The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment.

Via Investor's Business Daily

Gilead Sciences Unusual Options Activity For September 20 ↗

September 20, 2024

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗

September 13, 2024

Via Benzinga

What the Options Market Tells Us About Gilead Sciences ↗

September 12, 2024

Via Benzinga

Peering Into Gilead Sciences's Recent Short Interest ↗

September 06, 2024

Via Benzinga

3 Dirt Cheap Stocks to Buy Right Now ↗

September 21, 2024

Bargain hunters should love these great stocks.

Via The Motley Fool

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields ↗

September 20, 2024

Via Benzinga

Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗

September 14, 2024

These two stocks have had their issues in recent years, but both look like reliable long-term bets.

Via The Motley Fool

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

In drug development, solid performance in large-scale clinical trials is crucial.

Topics ETFs

Why Gilead Sciences Stock Thrashed the Market Today ↗

September 12, 2024

Via The Motley Fool

Unveiling 10 Analyst Insights On Gilead Sciences ↗

September 04, 2024

Via Benzinga

Gilead Sciences Options Trading: A Deep Dive into Market Sentiment ↗

September 03, 2024

Via Benzinga

Decoding Gilead Sciences's Options Activity: What's the Big Picture? ↗

August 27, 2024

Via Benzinga

Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections ↗

September 12, 2024

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by...

Via Benzinga

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention ↗

September 12, 2024

The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs.

Via Investor's Business Daily

Topics Intellectual Property

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

September 12, 2024

The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.

Biotech Breakout: Stocks for Your Watchlist

September 12, 2024

Via MarketBeat

Topics ETFs

$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗

August 22, 2024

Via Benzinga

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

September 10, 2024

Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels.

Four Stocks To Watch This Week - Monday, Sept 9 ↗

September 09, 2024

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

September 05, 2024

Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals.

Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street ↗

September 03, 2024

Via Benzinga

Biotech And Life Science Sector Update Summer Of 2024 ↗

August 29, 2024

It’s the slowest week of the year, we are at the market top and most earnings reports are good.

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats ↗

August 26, 2024

The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.

Via Investor's Business Daily

Gilead Sciences to Present at Upcoming Investor Conferences

August 21, 2024

Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.

Biotech Bull Market: 3 Ways To Play It ↗

August 20, 2024